6 February 2020
Melbourne, Australia: Sienna Cancer Diagnostics Ltd (ASX:SDX) (“Sienna” or “the Company”) is pleased to announce the appointment of Tony Di Pietro as a Director of its Board. Tony has held the role of CFO and Company Secretary with the Company for more than five years. He is a Chartered Accountant and a graduate member of the Governance Institute of Australia (a recognised Company Secretarial/Governance qualification) and has over 20 years of accounting and finance experience, with the last 15 years in the Biotechnology/Medtech industry.
With the departure of Dr David Earp in November 2019, Sienna’s Board was reduced to three members, which is the minimum number of directors under the Company’s constitution. The Board believes it is prudent risk management to appoint a fourth director to ensure ongoing compliance with the Company’s constitution and the Corporations Act. The Company will continue its search for an additional Non-Executive Director to ensure that an appropriate balance of independent directors is maintained. The Board regularly evaluates the skills and experience required to be represented on the Board and will add appropriate Board members when necessary to support and govern the business’ operations.
Sienna’s Chairman, Geoffrey Cumming, said “Tony’s experience at Sienna, combined with his strong governance background, qualify him for this role and we welcome him to the Board”.
For further information, please contact:
|Carl Stubbings, CEO/Managing Director
Sienna Cancer Diagnostics Ltd
+61 3 8288 2141
|Tony Di Pietro, CFO & Company Secretary
Sienna Cancer Diagnostics Ltd
+61 3 8288 2141
The release of this announcement was authorised by Geoffrey Cumming, Chairman.
About Sienna Cancer Diagnostics
Sienna Cancer Diagnostics Ltd is an Australian medical technology company with operations in the United States, Europe, Asia, Latin America and Australia. Sienna’s strengths lie in the identification, development and commercialisation of novel IVD technologies that satisfy an unmet clinical / market need. The Company has taken its first product, an IVD test for the biomarker hTERT, from research, through development, manufacturing, product registration, and market launch through a growing network of distribution partners.
The Company is focused on growing revenues from the existing product, increasing market access through new distribution partners, extending the applications for their hTERT test, and expanding their product offerings with the addition of new technologies into the product development pipeline.
Sienna’s most recent technology acquisition was a unique technology for the capture and isolation of target analytes in liquid biopsy samples. The sample preparation technology, known as SIEN-NET™, can more accurately and rapidly prepare samples for the liquid biopsy testing of a range of clinically useful biomarkers including exosomes, lipids, proteins, and other molecular targets of interest.
Forward Looking Statements
This announcement may contain forward-looking statements, which include all matters that are not historical facts. These forward-looking statements speak only as at the date of this announcement. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by forward-looking statements. Without limitation, indications of, and guidance on, future earnings and financial position and performance are examples of forward-looking statements. No representation, warranty or assurance (express or implied) is given or made by Sienna that the forward-looking statements contained in this announcement are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of Sienna, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward-looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.
Click here to read the full media release.